Genenews adds two members to its Board of Directors

07-May-2008

GeneNews Limited announced its shareholders recently elected two additional members to its Board of Directors, Mr. Harry A. Glorikian and Ms. Fran Tuttle. They join Mr. Rory Riggs, Mr. James Howard-Tripp, Mr. Garth MacRae, Dr. Heiner Dreismann, Dr. C. C. Liew and Dr. K. Wayne Marshall on the Company's Board of Directors.

Prior to becoming the Managing Partner at Scientia Advisors, Mr. Glorikian spent more than 8 years at Applied Biosystems in various roles, completing his tenure as Senior Manager, New Technology Assessment/Business Development. He was also the National Sales Manager for Signet Laboratories and a founder of X-Cell Laboratories, a clinical reference laboratory in San Francisco.

Ms. Tuttle is currently the President and CEO of HX Diagnostics. Throughout her career, she has developed and launched several major diagnostics products and had corporate experience at leading diagnostic companies including Bayer, Corning, Inc., Novartis, and Chiron. Ms. Tuttle was a Senior Vice President at Bayer Diagnostics responsible for a worldwide business of $400M. Most recently Ms. Tuttle was President and CEO of Protedyne, Inc., a robotics company developing automation solutions for molecular diagnostics and drug discovery, which was sold to LabCorp in 2007.

Other news from the department people

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

10+ products
4 whitepaper
10+ brochures
View topic world

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

10+ products
4 whitepaper
10+ brochures